Psilocybin | Jotup

Optimi Health To Host MDMA Educational Quality Assurance Webinar For Clinicians And Practitioners

Retrieved on:

Tuesday, February 6, 2024

PTSD, Chase, Research, FRA, Quality assurance, Safety, Psilocybin, PST, FDA, MDMA, Food, Trust, Health, Lycus, GMP, NDA, Pharmacist, Pharmaceutical industry

VANCOUVER, Feb. 06, 2024 (GLOBE NEWSWIRE) -- Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FRA: 8BN) (“Optimi”), a licensed Canadian drug researcher and formulator specializing in controlled psychedelic substances such as natural psilocybin and MDMA, is announcing an informative webinar titled “Know Your Drug Candidate: Safeguarding Quality in Psychedelic Therapy.” This event, scheduled for Tuesday, February 13, 2024, at 2:00 p.m. Pacific Standard Time (PST), is a crucial opportunity for clinicians, scientists, researchers, therapists, pharmacists, and regulators involved or interested in the GMP manufacturing of psychedelic drug substances.

Key Points:

Optimi Chief Science and Quality Assurance experts to provide in-depth access into the Company’s safety and quality standards.
Optimi experts will address critical inquiries which still exist on the definition of validated GMP psilocybin, MDMA, and other psychedelic substances.
Optimi is the only end-to-end, publicly listed psychedelics company currently offering its drug candidates at scale to address accessibility through lower costs.
Both individuals, considered experts in their respective fields, currently lead the Company's cutting-edge science and quality assurance divisions.

Police Seizures of Psychedelic Drugs Are Soaring Throughout the United States

Retrieved on:

Tuesday, February 6, 2024

Their analysis of national and state-level trafficking data revealed that across the country, seizures of psilocybin rose from 402 confiscations in 2017 to 1,393 confiscations in 2022.

Key Points:

Their analysis of national and state-level trafficking data revealed that across the country, seizures of psilocybin rose from 402 confiscations in 2017 to 1,393 confiscations in 2022.
The amount of the seized drugs nearly quadrupled, from 226 kilograms to 844 kilograms in the same time frame.
"Our findings, which uncover an increase in confiscations of psilocybin, suggest that popularity and availability of this psychedelic may be increasing," said study lead author Joseph Palamar, PhD, MPH.
For example, some of the reports in the data reference large shipments that may have been headed to other states for sale.

Clarion Clinics Open for Psychedelic-Assisted Treatments

Retrieved on:

Thursday, February 1, 2024

PTSD, Post-traumatic stress disorder, Clarion, TGA, Prohibition of drugs, Therapeutic Goods Administration, Clinical trial, Environment, Patient, Safety, Depression, Psilocybin, TRD, MDMA, Authorization, Psychotherapy, Schedule, Pharmaceutical industry

MELBOURNE, Australia and NEW YORK, Feb. 01, 2024 (GLOBE NEWSWIRE) -- Incannex Healthcare Inc (Nasdaq: IXHL) (‘Incannex’ or ‘the Company’) a pharmaceutical company developing proprietary medicinal cannabinoid products and psychedelic assisted psychotherapies for unmet needs is pleased to announce that Clarion Clinic’s co-Founder and Head of Psychiatry, Professor Suresh Sundram, has received Authorised Prescriber approval from the Therapeutic Goods Administration (TGA) to prescribe MDMA in the treatment of Post-traumatic Stress Disorder (PTSD) and psilocybin for Treatment-resistant Depression (TRD) at its first built-for-purpose clinic based in Melbourne, Australia, a city of approximately 5.2M people.

Key Points:

Clarion Clinics’ built-for-purpose clinic in Melbourne is now open for treatment, and will begin screening patients immediately.
Clarion Clinics is a collaboration between Australia’s leading psychedelic-assisted therapy professionals and scientists, and Incannex.
Clarion Clinics, Abbottsford, will be the first dedicated psychedelic-assisted therapy clinic in Australia.
Clarion is at the leading edge of mental healthcare, has the right protocols, and an experienced team ready to help people through these challenging conditions,” Peter Widdows, Incannex Director responsible for Clarion Clinics, said.

PharmAla granted a Controlled Drugs & Substances Dealer’s License by Health Canada

Retrieved on:

Thursday, January 25, 2024

Psilocybin, MDMA, Patient, Research, Science, SAP, Prohibition of drugs, Sale, Substance, OTC, Special access program, CDSL, Access, MDXX, Health Canada, Pharmaceutical industry

VANCOUVER, British Columbia, Jan. 25, 2024 (GLOBE NEWSWIRE) -- PharmAla Biotech Holdings Inc. (“PharmAla” or the “Company”) (CSE: MDMA) (OTC:MDXXF), a biotechnology company focused on the research, development, and manufacturing of LaNeo™ MDMA and novel derivatives of MDMA (MDXX class molecules), is pleased to announce that it has been granted a Controlled Drugs & Substances Dealer’s License (CDSL) by Health Canada, Canada’s federal health regulator.

Key Points:

VANCOUVER, British Columbia, Jan. 25, 2024 (GLOBE NEWSWIRE) -- PharmAla Biotech Holdings Inc. (“PharmAla” or the “Company”) (CSE: MDMA) (OTC:MDXXF), a biotechnology company focused on the research, development, and manufacturing of LaNeo™ MDMA and novel derivatives of MDMA (MDXX class molecules), is pleased to announce that it has been granted a Controlled Drugs & Substances Dealer’s License (CDSL) by Health Canada, Canada’s federal health regulator.
The CDSL allows PharmAla to offer for sale both 3,4 Methylenedioxymethamphetamine (MDMA) and Psilocybin to those authorized to legally hold these materials.
“PharmAla is breaking new ground in the Canadian market.
“This license could drive revenue growth for the Company, and allow us to educate potential prescribers on the relevant science behind LaNeo™ and MDMA Therapy.

How Psychedelic-Based Therapeutics Are Advancing in Treating Generalized Anxiety Disorder (GAD) Condition

Retrieved on:

Wednesday, January 24, 2024

PALM BEACH, Fla., Jan. 24, 2024 /PRNewswire/ -- The coming years could see a massive shift in the U.S. government's approach to regulating hallucinogenic drugs. Several biopharma companies are developing psychedelics-based treatments for various mental health conditions like Generalized Anxiety Disorder (GAD). GAD is a prevalent mental health condition characterized by excessive and persistent worry, often extending beyond specific triggers. Individuals with GAD experience heightened levels of anxiety, anticipating future events and exhibiting physical symptoms such as muscle tension and restlessness. The disorder significantly impairs daily functioning and quality of life. A report from Delveinsight said that the total market size of the Generalized Anxiety Disorder (GAD) treatment market is anticipated to experience growth during the forecast period (2032) due to the emergence of new and effective treatments, especially numerous trials developing new and innovative next-generation psychedelic treatment options. The report added: "The diagnosis of Generalized Anxiety Disorder (GAD) involves a comprehensive assessment of an individual's mental health, considering the presence of excessive and uncontrollable worry across various aspects of life for a minimum of six months. Clinicians utilize standardized psychiatric interviews and validated screening tools to evaluate the severity of anxiety symptoms, along with a thorough exploration of associated physical and psychological manifestations. Differential diagnosis is crucial to rule out other psychiatric conditions, medical disorders, or substance-related issues that may mimic GAD symptoms. The diagnostic process also entails considering the impact of anxiety on daily functioning and its persistence in the absence of identifiable stressors. A multidimensional approach aids in ensuring an accurate diagnosis and facilitates the development of an effective treatment plan tailored to the individual's needs." Active Companies active today in markets include: Cybin Inc. (NYSE: CYBN) (NEO: CYBN), COMPASS Pathways plc (NASDAQ: CMPS), Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) (NEO: MMED), Seelos Therapeutics, Inc. (NASDAQ: SEEL), atai Life Sciences (NASDAQ: ATAI).

Key Points:

Several biopharma companies are developing psychedelics-based treatments for various mental health conditions like Generalized Anxiety Disorder (GAD).
It continued: "DelveInsight's analyst projects that among the total diagnosed prevalent cases of Generalized Anxiety Disorder (GAD) in 7MM approximately 53% of cases were from the US.
The Generalized Anxiety Disorder (GAD) market is projected to witness consistent growth throughout the forecast period (2023–2032).
The market size of Generalized Anxiety Disorder (GAD) in the 7MM is expected to increase, driven by better diagnosis and the launch of emerging therapies."

How Psychedelic-Based Therapeutics Are Advancing in Treating Generalized Anxiety Disorder (GAD) Condition

Retrieved on:

Wednesday, January 24, 2024

PALM BEACH, Fla., Jan. 24, 2024 /PRNewswire/ -- The coming years could see a massive shift in the U.S. government's approach to regulating hallucinogenic drugs. Several biopharma companies are developing psychedelics-based treatments for various mental health conditions like Generalized Anxiety Disorder (GAD). GAD is a prevalent mental health condition characterized by excessive and persistent worry, often extending beyond specific triggers. Individuals with GAD experience heightened levels of anxiety, anticipating future events and exhibiting physical symptoms such as muscle tension and restlessness. The disorder significantly impairs daily functioning and quality of life. A report from Delveinsight said that the total market size of the Generalized Anxiety Disorder (GAD) treatment market is anticipated to experience growth during the forecast period (2032) due to the emergence of new and effective treatments, especially numerous trials developing new and innovative next-generation psychedelic treatment options. The report added: "The diagnosis of Generalized Anxiety Disorder (GAD) involves a comprehensive assessment of an individual's mental health, considering the presence of excessive and uncontrollable worry across various aspects of life for a minimum of six months. Clinicians utilize standardized psychiatric interviews and validated screening tools to evaluate the severity of anxiety symptoms, along with a thorough exploration of associated physical and psychological manifestations. Differential diagnosis is crucial to rule out other psychiatric conditions, medical disorders, or substance-related issues that may mimic GAD symptoms. The diagnostic process also entails considering the impact of anxiety on daily functioning and its persistence in the absence of identifiable stressors. A multidimensional approach aids in ensuring an accurate diagnosis and facilitates the development of an effective treatment plan tailored to the individual's needs." Active Companies active today in markets include: Cybin Inc. (NYSE: CYBN) (NEO: CYBN), COMPASS Pathways plc (NASDAQ: CMPS), Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) (NEO: MMED), Seelos Therapeutics, Inc. (NASDAQ: SEEL), atai Life Sciences (NASDAQ: ATAI).

Key Points:

Several biopharma companies are developing psychedelics-based treatments for various mental health conditions like Generalized Anxiety Disorder (GAD).
It continued: "DelveInsight's analyst projects that among the total diagnosed prevalent cases of Generalized Anxiety Disorder (GAD) in 7MM approximately 53% of cases were from the US.
The Generalized Anxiety Disorder (GAD) market is projected to witness consistent growth throughout the forecast period (2023–2032).
The market size of Generalized Anxiety Disorder (GAD) in the 7MM is expected to increase, driven by better diagnosis and the launch of emerging therapies."

Sheppard Pratt Announces Dr. Matthew W. Johnson as Senior Researcher for the Center of Excellence for Psilocybin Research and Treatment

Retrieved on:

Thursday, January 18, 2024

The Center of Excellence for Psilocybin Research and Treatment is the first leading global site for the development of psychedelic therapeutics in the U.S.

Key Points:

The Center of Excellence for Psilocybin Research and Treatment is the first leading global site for the development of psychedelic therapeutics in the U.S.
In his role as senior researcher, Dr. Johnson will join Sheppard Pratt in their efforts to integrate biological psychiatry with psychotherapy.
Sheppard Pratt's Center of Excellence for Psilocybin Research and Treatment brings together evidence-based innovation and the development of psychedelic therapeutics on a large scale.
To learn more about Sheppard Pratt's Institute for Advanced Diagnostics and Therapeutics and Center of Excellence for Psilocybin Research and Treatment, visit www.sheppardpratt.org/the-institute-for-advanced-diagnostics-and-therape... .

VA Signals Historic Policy Shift By Funding First-Ever Psychedelic Studies for Veterans

Retrieved on:

Monday, January 8, 2024

Veteran, Public policy, Policy, Research, Depression, FDA, Hope, Psilocybin, Member, Congress, MDMA, PTSD, Investment, RFA, Diagnosis, Skin, Suicide, House, Pharmaceutical industry

WASHINGTON, Jan. 8, 2024 /PRNewswire/ -- Last Friday, the Department of Veterans Affairs issued a Request for Applications (RFA) to study the use of FDA-designated Breakthrough Therapies, including MDMA-Assisted Therapy and psilocybin, to treat veterans who suffer from PTSD and depression. This announcement marks the VA's first-ever direct investment in support of these studies, and signals a significant policy shift in favor of MDMA and psychedelic-assisted therapies within the VA health care system. The VA's announcement marks a huge victory for the leading federal veteran advocacy group for MDMA-Assisted Therapy, Healing Breakthrough.

Key Points:

VA issues Request for Applications (RFA) to study the efficacy of psychedelic compounds in treating veterans who suffer from PTSD and depression.
This announcement marks the VA's first-ever direct investment in support of these studies, and signals a significant policy shift in favor of MDMA and psychedelic-assisted therapies within the VA health care system.
The VA's announcement marks a huge victory for the leading federal veteran advocacy group for MDMA-Assisted Therapy, Healing Breakthrough.
The VA's decision to put skin in the game by funding veteran-specific studies on MDMA and psychedelics is more than just a historic event for those like me who recognize these compounds' life-saving potential.

Lobe Sciences Provides Company Review of 2023

Retrieved on:

Monday, January 8, 2024

Biotechnology, Neurology, Health, Pharmaceutical, Clinical Trials, Pharmacokinetics, Acquisition, Conference, Psilocybin, Sickle cell disease, Therapy, OTCQB, Philip Young, Pharmaceutical industry

Lobe Sciences Ltd. (OTCQB: LOBEF) (CSE: LOBE) ("Lobe" or the "Company"), a biopharmaceutical company focused on developing transformative medicines to treat rare diseases today provided an update from the Company on its progress and achievements in 2023.

Key Points:

Lobe Sciences Ltd. (OTCQB: LOBEF) (CSE: LOBE) ("Lobe" or the "Company"), a biopharmaceutical company focused on developing transformative medicines to treat rare diseases today provided an update from the Company on its progress and achievements in 2023.
Philip Young CEO commented, “2023 was a remarkable year that witnessed the company make important advancements in clinical development of our proprietary pharmaceutical products and the acquisition and commercial launch of Altemia, our novel medical formulation for Sickle Cell Disease.”
Confirmed the improved pharmacokinetics of L-130 delivered as a shelf-stable capsule over its inactive prodrug, psilocybin
“2023 was truly a transformative year for Lobe Sciences.
The company plans to build on this momentum in 2024 and I look forward to updating our investors throughout 2024.”
Management will be meeting with prospective investors and corporate partners during the 42nd Annual J.P. Morgan Healthcare Conference in San Francisco on January 8-11.
To schedule a meeting please contact [email protected]

SciSparc and Clearmind Medicine Reflect on Successful Collaboration in 2023 Aiming to Upgrade Wide Range of Psychedelic-Based Treatments

Retrieved on:

Thursday, January 4, 2024

TEL, Psilocybin, Patent, CWY, MDMA, LSD, Lysergic acid diethylamide, IP, PEA, Central nervous system, Patient, Safety, Therapy, Disorder, DMT, Pharmaceutical industry

TEL AVIV, Israel, Jan. 04, 2024 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) ("Company" or "SciSparc"), a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders and rare diseases of the central nervous system, reflects on the successful collaboration in 2023 with Clearmind Medicine Inc. (“Clearmind") (Nasdaq: CMND) (CSE: CMND) (FSE: CWY), a biotech company focused on the discovery and development of novel psychedelic-derived therapeutics to solve major under-treated health problems. Early in 2023, Clearmind filed six provisional patent applications with the United States Patent and Trademark Office (USPTO) for unique combinations of future psychedelic-based compounds, as part of its ongoing collaboration with SciSparc.

Key Points:

Early in 2023, Clearmind filed six provisional patent applications with the United States Patent and Trademark Office (USPTO) for unique combinations of future psychedelic-based compounds, as part of its ongoing collaboration with SciSparc.
The patent applications are for novel proprietary combinations of lysergic acid diethylamide (LSD), psilocybin, N,N-dimethyltryptamine (DMT) and Palmitoylethanolamide (PEA) and novel proprietary combinations of 3,4-Methylenedioxymethamphetamine (MDMA), Ibogaine, Ketamine, and PEA.
PEA is the active ingredient of SciSparc’s proprietary CannAmide™.
As part of the collaboration agreement between SciSparc and Clearmind, originally announced on March 8,2022, any assets generated from the collaboration shall be jointly owned by SciSparc and Clearmind.